8-K: Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering

Phio Pharmaceuticals Corp. has announced a $1.83 million registered direct offering priced at-the-market under Nasdaq rules, along with a concurrent private placement of warrants.

Summary

• Phio Pharmaceuticals Corp. has entered into agreements for a registered direct offering of 610,000 shares of its common stock at $3.00 per share, resulting in gross proceeds of $1.83 million.
• The company will also issue unregistered warrants to purchase up to 1,220,000 shares of common stock in a concurrent private placement.
• The warrants have an exercise price of $3.00 per share, are exercisable upon issuance, and expire 24 months from the issuance date.
• H.C. Wainwright & Co. is the exclusive placement agent for the offering, which is expected to close around January 17, 2025, pending customary closing conditions.
• Phio intends to use the net proceeds for working capital and general corporate purposes.

Sentiment

Score: 6

Explanation: The announcement is neutral. While the capital raise is necessary for the company's operations, it also involves dilution for existing shareholders. The terms of the offering appear to be standard for the industry.

Positives

• The offering is expected to provide Phio Pharmaceuticals with $1.83 million in gross proceeds for working capital and general corporate purposes.
• The warrants provide potential for additional capital if exercised.
• The offering is priced at-the-market, which can be seen as a positive as it reflects the current market value of the shares.

Negatives

• The offering involves the issuance of new shares, which may dilute existing shareholders' ownership.
• The warrants, if exercised, would further dilute existing shareholders' ownership.
• The company is relying on future financing, which may not be available on favorable terms or at all.

Risks

• The closing of the offering is subject to customary closing conditions and may not occur as expected.
• The company's use of proceeds may not be effective in improving its financial condition or business prospects.
• The market price of Phio Pharmaceuticals' common stock could be negatively impacted by the offering.
• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Industry Context

This type of financing is common for clinical-stage biotechnology companies to fund ongoing research and development activities.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as [Hypothetical Biotech Company A] and [Hypothetical Biotech Company B], have also utilized registered direct offerings and private placements to raise capital.
• The terms of this offering, including the share price and warrant coverage, appear to be within the typical range for similar transactions in the current market environment.
• However, the specific terms and conditions should be compared to those of recent offerings by companies with similar market capitalizations and clinical development stages to determine whether they are favorable or unfavorable to Phio Pharmaceuticals.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's ability to fund its operations and continue its clinical development programs is enhanced.
• The company's financial stability is improved.

Next Steps

• The offering is expected to close on or about January 17, 2025, subject to customary closing conditions.
• The company will file a prospectus supplement with the SEC.
• The company will use the net proceeds for working capital and general corporate purposes.

Key Dates